Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Levothyroxine NDAs May Be Refused Filing After First Product Approval - FDA

Executive Summary

Levothyroxine NDAs may be refused filing following approval of the first levothyroxine product, FDA said in a draft guidance issued August 18.

You may also be interested in...



Abbott Synthroid NDA To Include Clinical Study Data; Citizen Petition Rejected

Abbott will file data from clinical studies, including bioavailability and pharmacokinetic data, to support its NDA for the thyroid agent Synthroid.

Abbott Synthroid NDA To Include Clinical Study Data; Citizen Petition Rejected

Abbott will file data from clinical studies, including bioavailability and pharmacokinetic data, to support its NDA for the thyroid agent Synthroid.

Glaxo To File ANDA For Lanoxin Elixir, Requests Two-Years For Approval

GlaxoSmithKline plans to file an ANDA for Lanoxin Elixir using the tablet formulation of its cardiac drug Lanoxin (digoxin) as its reference drug.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS034715

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel